Telix Pharmaceuticals (TLX) Common Equity (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Common Equity for 3 consecutive years, with $415.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity rose 11.78% year-over-year to $415.4 million; the TTM figure through Dec 2025 stood at $415.4 million (up 11.78% YoY), while the FY2025 annual figure was $415.4 million, up 17.69% from the prior year.
• Common Equity rose to $415.4 million in Q4 2025 per TLX's latest filing, from $371.6 million in the prior quarter.
• Across five years, Common Equity topped out at $415.4 million in Q4 2025 and bottomed at $96.9 million in Q4 2023.
• Historically, Common Equity has averaged $294.6 million across 3 years, with a median of $371.6 million in 2024.
• Annual changes were most pronounced in 2024 — Common Equity jumped 283.32% — and 2025, when it grew 11.78%.
• Telix Pharmaceuticals' Common Equity stood at $96.9 million in 2023, then surged by 283.32% to $371.6 million in 2024, then gained by 11.78% to $415.4 million in 2025.
• Business Quant data shows TLX's Common Equity at $415.4 million in Q4 2025, $371.6 million in Q4 2024, and $96.9 million in Q4 2023.